Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
Abstract Background Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T50, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To...
Main Authors: | Amin Ussif, Hege Pihlstrøm, Andreas Pasch, Hallvard Holdaas, Anders Hartmann, Knut Smerud, Anders Åsberg |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-08-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-018-1000-8 |
Similar Items
-
Comparison of the Effects of Paricalcitol and Calcitriol on Vascular Calcification in Patients Undergoing Chronic Hemodialysis
by: Süleyman Karaköse, et al.
Published: (2021-08-01) -
Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus ParicalcitolPlain-Language Summary
by: Karim H. Anis, et al.
Published: (2020-07-01) -
Paricalcitol in management of chronic kidney disease–mineral and bone disorder
by: A. K. Eremkina, et al.
Published: (2021-04-01) -
Calciprotein Particles and Serum Calcification Propensity: Hallmarks of Vascular Calcifications in Patients with Chronic Kidney Disease
by: Ciprian N. Silaghi, et al.
Published: (2020-04-01) -
Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial
by: Iain Bressendorff, et al.
Published: (2017-05-01)